Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics, Inc. | 2025-10-16 18:47:29 | 2.64 | -0.01 | -0.35 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESPR | 0001434868 | Esperion Therapeutics, Inc. | US29664W1053 | 549300OFU56UKEWVUS92 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 3891 RANCHERO DRIVE, SUITE 150 | ANN ARBOR | MI | 48108 | UNITED STATES | US | 734-887-3903 | 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108 | 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108 | HDL THERAPEUTICS INC | Pharmaceutical | 2008 | Sheldon Koenig | — | http://www.esperion.com/ | 435,100,000 | 202,149,464 | 201,622,825 | Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. | 2025-10-10 21:41:45 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 435,100,000 | 292,600,000 | 205.3333 | 197,848,886 | 12,796,181 | 6.9149 |
| 2023 | 142,500,000 | -279,800,000 | -66.2562 | 185,052,705 | 108,479,875 | 141.6689 |
| 2022 | 422,300,000 | -170,200,000 | -28.7257 | 76,572,830 | 13,751,227 | 21.8893 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Joanne Foody | Chief Medical Officer | 2024 | 388,288 | 0 | 307,500 | 195,200 | 595,860 | 1,870,559 |
| Benjamin Looker | General Counsel | 2024 | 471,000 | 0 | 205,000 | 213,750 | 11,600 | 1,130,827 |
| Sheldon L. Koenig | Chief Executive Officer, President | 2024 | 745,833 | 0 | 930,700 | 487,500 | 29,045 | 3,175,240 |
| Benjamin Halladay | Chief Financial Officer | 2024 | 467,333 | 0 | 348,500 | 235,125 | 11,500 | 1,368,427 |
| Eric Warren | Chief Commercial Officer | 2024 | 481,867 | 0 | 205,000 | 218,250 | 15,250 | 1,149,844 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 304 |
| 2023 | 240 |
| 2022 | 199 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 332,314,000 | 116,334,000 | 75,475,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 46,238,000 | 86,107,000 | 118,927,000 |
| General And Administrative Expenses | 163,073,000 | 142,523,000 | 109,082,000 |
| Operating Expenses | 277,912,000 | 271,897,000 | 254,976,000 |
| Operating Income | 54,402,000 | -155,563,000 | -179,501,000 |
| Net Income | -51,745,000 | -209,248,000 | -233,659,000 |
| Earnings Per Share Basic | -0.28 | -2.03 | -3.52 |
| Earnings Per Share Diluted | -0.28 | -2.03 | -3.52 |
| Weighted Average Shares Outstanding Basic | 187,181,856 | 103,106,616 | 66,407,242 |
| Weighted Average Shares Outstanding Diluted | 187,181,856 | 103,106,616 | 66,407,242 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 144,761,000 | 82,248,000 | 124,775,000 |
| Marketable Securities Current | — | 0 | 42,086,000 |
| Accounts Receivable | 80,142,000 | 48,494,000 | 33,729,000 |
| Inventories | 94,491,000 | 65,623,000 | 35,201,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 337,998,000 | 201,065,000 | 246,683,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 254,000 | 0 | 164,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 5,823,000 | 4,731,000 | 1,256,000 |
| Total Assets | 343,821,000 | 205,796,000 | 247,939,000 |
| Accounts Payable | 51,650,000 | 31,718,000 | 23,040,000 |
| Deferred Revenue | 8,518,000 | 25,402,000 | 3,507,000 |
| Short Term Debt | 54,912,000 | — | — |
| Other Liabilities Current | — | 990,000 | 279,000 |
| Total Liabilities Current | 246,233,000 | 156,224,000 | 92,308,000 |
| Long Term Debt | 54,600,000 | 261,600,000 | 259,900,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 486,310,000 | 504,566,000 | 479,409,000 |
| Total Liabilities | 732,543,000 | 660,790,000 | 571,717,000 |
| Common Stock | 196,000 | 118,000 | 75,000 |
| Retained Earnings | -1,601,029,000 | -1,549,284,000 | -1,340,036,000 |
| Accumulated Other Comprehensive Income | 0 | 0 | -2,000 |
| Total Shareholders Equity | -388,722,000 | -454,994,000 | -323,778,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 63,000 | 164,000 | 500,000 |
| Share Based Compensation Expense | 11,993,000 | 11,958,000 | 15,215,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 31,648,000 | 14,765,000 | 10,795,000 |
| Change In Inventories | 28,868,000 | 30,422,000 | 807,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 12,432,000 | 8,678,000 | 5,603,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -23,654,000 | -135,487,000 | -174,827,000 |
| Purchases Of Marketable Securities | 0 | 0 | 59,897,000 |
| Sales Of Marketable Securities | 0 | 42,500,000 | 68,001,000 |
| Acquisition Of Property Plant And Equipment | 317,000 | — | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -317,000 | 42,500,000 | 8,104,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 513,000 | 4,448,000 | 90,849,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 29,000 | — | — |
| Cash From Financing Activities | 86,484,000 | 50,460,000 | 32,606,000 |
| Change In Cash | 62,513,000 | -42,527,000 | -134,117,000 |
| Cash At End Of Period | 144,761,000 | 82,248,000 | 124,775,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | 58,976,000 | 56,810,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.28 | -2.03 | -3.52 |
| Price To Earnings Ratio | -7.8571 | -1.4729 | -1.7699 |
| Earnings Growth Rate | -86.2069 | -42.3295 | -62.1912 |
| Price Earnings To Growth Ratio | 0.0911 | 0.0348 | 0.0285 |
| Book Value Per Share | -2.0767 | -4.4128 | -4.8756 |
| Price To Book Ratio | -1.0594 | -0.6776 | -1.2778 |
| Ebitda | 7,569,000 | -150,108,000 | -176,349,000 |
| Enterprise Value | 376,551,083.2 | 487,640,781.84 | 548,842,117.66 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -0.2817 | -0.575 | -0.8027 |
| Capital Expenditures | 317,000 | 0 | 0 |
| Free Cash Flow | -23,971,000 | -135,487,000 | -174,827,000 |
| Return On Equity | 0.1331 | 0.4599 | 0.7217 |
| One Year Beta | 1.522 | 1.0266 | 0.8513 |
| Three Year Beta | 0.9909 | 0.8532 | 0.9401 |
| Five Year Beta | 0.9894 | 0.961 | 1.0321 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Halladay Benjamin | Chief Financial Officer | 2025-09-17 | 7,046 | D | 474,862 |
| Koenig Sheldon L. | Director, President and CEO | 2025-09-17 | 28,427 | D | 1,518,831 |
| Looker Benjamin | General Counsel | 2025-09-17 | 6,267 | D | 393,670 |
| Halladay Benjamin | Chief Financial Officer | 2025-07-17 | 11 | D | 474,462 |
| Looker Benjamin | General Counsel | 2025-07-17 | 1,304 | D | 399,937 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| City State Bank | 2025-09-30 | 530 | 200 | 2.65 |
| Capital Advisors Wealth Management, LLC | 2025-09-30 | 112,771 | 42,555 | 2.65 |
| CWM, LLC | 2025-09-30 | 52,000 | 19,674 | 2.6431 |
| DAVENPORT & Co LLC | 2025-09-30 | 26,500 | 10,000 | 2.65 |
| VOYA INVESTMENT MANAGEMENT LLC | 2025-09-30 | 100,689 | 37,996 | 2.65 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Jacob Funds Inc. | 2025-08-31 | Institutional Class | JMIGX | 94,000 | 208,680 | 1.292 |
| Jacob Funds Inc. | 2025-08-31 | Investor Class | JMCGX | 94,000 | 208,680 | 1.292 |
| Jacob Funds Inc. | 2025-08-31 | Investor Class | JSCGX | 120,000 | 266,400 | 2.6464 |
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 882 | 1,252.44 | 0.0005 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 349,019 | 495,606.98 | 0.0209 |